{"id":40453,"date":"2021-05-03T07:31:39","date_gmt":"2021-05-03T07:31:39","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=40453"},"modified":"2021-05-04T19:25:57","modified_gmt":"2021-05-04T19:25:57","slug":"us-post-authorisation-safety-data-on-pfizer-and-moderna-vaccines","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/40453","title":{"rendered":"US post-authorisation safety data on Pfizer and Moderna vaccines"},"content":{"rendered":"
\n

<\/strong><\/span>Simon Collins, HIV i-Base<\/strong><\/p>\n<\/div>\n

\n

Results from the first two months of the US <\/span>surveillance programme for the first two vaccines authorised in the US – both using mRNA – are published in JAMA.<\/strong><\/p>\n<\/div>\n

\n

The programme – called V-safe – allows people to voluntarily enrol to received mobile text message survey links from daily for seven days after an injection with longer-term prompts over 12 months.<\/p>\n<\/div>\n

\n

Questions include local and systemic reactions (injection site pain, fatigue, headache etc), but not allergic reactions. A free-text box is also included. Medical events prompted telephone follow-up.<\/p>\n<\/div>\n

\n

From a total of 46 million people vaccinated, just over 3.6 million [people who completed at least one survey, Approximately 1.9 million people also completed a survey following the second dose.<\/p>\n<\/div>\n

\n

Most people reported injection site reactions (dose 1: 70%; dose 2: 75%) or a systemic reaction (dose 1: 50%; dose 2: 69%) and <\/span>injection site pain (67%), fatigue (31%), headache (26%), and myalgia (19%) were very common. Although reactions were significantly higher after the second dose, this might have biased people to complete the second surveys.<\/span><\/p>\n<\/div>\n

\n

Reference<\/p>\n<\/div>\n

\n

Chapin-Bardales J et al. Reactogenicity following receipt of mRNA-Based COVID-19 vaccines.\u00a0JAMA.<\/i>\u00a0doi:10.1001\/jama.2021.5374. (5 April 2021).
\nhttps:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2778441<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Simon Collins, HIV i-Base Results from the first two months of the US surveillance programme for the first two vaccines authorised in the US – both using mRNA – are published in JAMA. The programme – called V-safe – allows …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[292,278],"tags":[],"class_list":["post-40453","post","type-post","status-publish","format-standard","hentry","category-covid-19-vaccine","category-covid-19"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40453","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=40453"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40453\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=40453"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=40453"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=40453"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}